These are the stocks posting the largest moves before the bell.Market Insiderread more
Home Depot's CEO says the retailer cut its outlook partly due to "the potential impacts to the U.S. consumer arising from recently announced tariffs."Retailread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
While the U.S. gave Huawei a 90-day reprieve, allowing American businesses to keep selling specific products to the Chinese firm, it also added more affiliates of the...Technologyread more
Energy stocks may be fueling up for a comeback rally. One technical analyst says that after the sector's pummeling, these two stocks look particularly good.Trading Nationread more
Dow set to drop; White House denies payroll tax cut report; China tweaks interest rates; Home Depot worries about trade war; Beyond Meat gets an upgradeMarketsread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Porsche and Apple believe music streaming is the next advancement for in-car entertainment. The luxury automaker and tech giant are teaming up to allow drivers of the all-new,...US: Consumer Servicesread more
"We think the stock is appealing once again," J.P. Morgan says of Beyond Meat.Marketsread more
U.K. Prime Minister Boris Johnson told the EU that a Brexit deal can still be approved by U.K. lawmakers if Brussels agrees to scrapping the contentious Irish "backstop."read more
One of Botox maker Allergan's newest drugs could flip the script when it comes to treating depression, Chairman and CEO Brent Saunders told CNBC on Monday.
"Rapastinel is a great drug that we have at Phase 3," Saunders told "Mad Money" host Jim Cramer. "We'll get the data [in the] early part of next year. It could be an absolute game-changer for depression."
Depression — and the suicides associated with it — is one of the top causes of death among younger generations.
According to the Anxiety and Depression Association of America, depression is the leading cause of disability in the United States in people between the ages of 15 and 44.
Allergan's drug, which is pending approval from the Food and Drug Administration based on the Phase 3 trial data, specifically targets treatment-resistant depression.
"I really am hopeful for this drug," Saunders said. "Mental health is a huge unmet medical need. Depression, suicidality – we're doing a suicidality study as well with this drug. This could be a game-changer. We're waiting for the data. I'm so excited for it."